Literature DB >> 30220580

WNT Signaling in Cancer Immunosurveillance.

Lorenzo Galluzzi1, Stefani Spranger2, Elaine Fuchs3, Alejandro López-Soto4.   

Abstract

Deregulated WNT signaling has been shown to favor malignant transformation, tumor progression, and resistance to conventional cancer therapy in a variety of preclinical and clinical settings. Accumulating evidence suggests that aberrant WNT signaling may also subvert cancer immunosurveillance, hence promoting immunoevasion and resistance to multiple immunotherapeutics, including immune checkpoint blockers. Here, we discuss the molecular and cellular mechanisms through which WNT signaling influences cancer immunosurveillance and present potential therapeutic avenues to harness currently available WNT modulators for cancer immunotherapy.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  BRAF; CTLA4; GSK3; PD-L1/PD-1 axis; cancer immunotherapy; tumor microenvironment; β-catenin

Mesh：

Substances：

Year:  2018        PMID： 30220580      PMCID： PMC7001864          DOI： 10.1016/j.tcb.2018.08.005

Source DB:  PubMed          Journal:  Trends Cell Biol        ISSN： 0962-8924            Impact factor:   20.808


  199 in total

1.  Noncanonical Wnt signaling maintains hematopoietic stem cells in the niche.

Authors:  Ryohichi Sugimura; Xi C He; Aparna Venkatraman; Fumio Arai; Andrew Box; Craig Semerad; Jeffrey S Haug; Lai Peng; Xiao-Bo Zhong; Toshio Suda; Linheng Li
Journal:  Cell       Date:  2012-07-20       Impact factor: 41.582

2.  Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma.

Authors:  Siyuan Zheng; Andrew D Cherniack; Ninad Dewal; Richard A Moffitt; Ludmila Danilova; Bradley A Murray; Antonio M Lerario; Tobias Else; Theo A Knijnenburg; Giovanni Ciriello; Seungchan Kim; Guillaume Assie; Olena Morozova; Rehan Akbani; Juliann Shih; Katherine A Hoadley; Toni K Choueiri; Jens Waldmann; Ozgur Mete; A Gordon Robertson; Hsin-Ta Wu; Benjamin J Raphael; Lina Shao; Matthew Meyerson; Michael J Demeure; Felix Beuschlein; Anthony J Gill; Stan B Sidhu; Madson Q Almeida; Maria C B V Fragoso; Leslie M Cope; Electron Kebebew; Mouhammed A Habra; Timothy G Whitsett; Kimberly J Bussey; William E Rainey; Sylvia L Asa; Jérôme Bertherat; Martin Fassnacht; David A Wheeler; Gary D Hammer; Thomas J Giordano; Roel G W Verhaak
Journal:  Cancer Cell       Date:  2016-05-09       Impact factor: 31.743

3.  Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy.

Authors:  Stefani Spranger; Daisy Dai; Brendan Horton; Thomas F Gajewski
Journal:  Cancer Cell       Date:  2017-05-08       Impact factor: 31.743

4.  Recurrent R-spondin fusions in colon cancer.

Authors:  Somasekar Seshagiri; Eric W Stawiski; Steffen Durinck; Zora Modrusan; Elaine E Storm; Caitlin B Conboy; Subhra Chaudhuri; Yinghui Guan; Vasantharajan Janakiraman; Bijay S Jaiswal; Joseph Guillory; Connie Ha; Gerrit J P Dijkgraaf; Jeremy Stinson; Florian Gnad; Melanie A Huntley; Jeremiah D Degenhardt; Peter M Haverty; Richard Bourgon; Weiru Wang; Hartmut Koeppen; Robert Gentleman; Timothy K Starr; Zemin Zhang; David A Largaespada; Thomas D Wu; Frederic J de Sauvage
Journal:  Nature       Date:  2012-08-30       Impact factor: 49.962

5.  Baseline β-catenin, programmed death-ligand 1 expression and tumour-infiltrating lymphocytes predict response and poor prognosis in BRAF inhibitor-treated melanoma patients.

Authors:  Daniela Massi; Emanuela Romano; Eliana Rulli; Barbara Merelli; Romina Nassini; Francesco De Logu; Ivan Bieche; Gianna Baroni; Laura Cattaneo; Gongda Xue; Mario Mandalà
Journal:  Eur J Cancer       Date:  2017-04-14       Impact factor: 9.162

6.  Frizzled 9 knock-out mice have abnormal B-cell development.

Authors:  Erik A Ranheim; Helen C K Kwan; Tannishtha Reya; Yu-Ker Wang; Irving L Weissman; Uta Francke
Journal:  Blood       Date:  2004-11-30       Impact factor: 22.113

7.  Cyclooxygenase-2 inhibition inhibits c-Met kinase activity and Wnt activity in colon cancer.

Authors:  Jurriaan B Tuynman; Louis Vermeulen; Elles M Boon; Kristel Kemper; Aeilko H Zwinderman; Maikel P Peppelenbosch; Dirk J Richel
Journal:  Cancer Res       Date:  2008-02-15       Impact factor: 12.701

8.  β-Catenin-mediated immune evasion pathway frequently operates in primary cutaneous melanomas.

Authors:  Jérémie Nsengimana; Jon Laye; Anastasia Filia; Sally O'Shea; Sathya Muralidhar; Joanna Poźniak; Alastair Droop; May Chan; Christy Walker; Louise Parkinson; Joanne Gascoyne; Tracey Mell; Minttu Polso; Rosalyn Jewell; Juliette Randerson-Moor; Graham P Cook; D Timothy Bishop; Julia Newton-Bishop
Journal:  J Clin Invest       Date:  2018-04-16       Impact factor: 14.808

9.  Transcriptional plasticity promotes primary and acquired resistance to BET inhibition.

Authors:  Philipp Rathert; Mareike Roth; Tobias Neumann; Felix Muerdter; Jae-Seok Roe; Matthias Muhar; Sumit Deswal; Sabine Cerny-Reiterer; Barbara Peter; Julian Jude; Thomas Hoffmann; Łukasz M Boryń; Elin Axelsson; Norbert Schweifer; Ulrike Tontsch-Grunt; Lukas E Dow; Davide Gianni; Mark Pearson; Peter Valent; Alexander Stark; Norbert Kraut; Christopher R Vakoc; Johannes Zuber
Journal:  Nature       Date:  2015-09-14       Impact factor: 49.962

10.  Glycogen Synthase Kinase 3 Inactivation Drives T-bet-Mediated Downregulation of Co-receptor PD-1 to Enhance CD8(+) Cytolytic T Cell Responses.

Authors:  Alison Taylor; James A Harker; Kittiphat Chanthong; Philip G Stevenson; Elina I Zuniga; Christopher E Rudd
Journal:  Immunity       Date:  2016-02-16       Impact factor: 31.745
View more
  71 in total

Review 1.  PDE5 and PDE10 inhibition activates cGMP/PKG signaling to block Wnt/β-catenin transcription, cancer cell growth, and tumor immunity.

Authors:  Gary A Piazza; Antonio Ward; Xi Chen; Yulia Maxuitenko; Alex Coley; Nada S Aboelella; Donald J Buchsbaum; Michael R Boyd; Adam B Keeton; Gang Zhou
Journal:  Drug Discov Today       Date:  2020-06-17       Impact factor: 7.851

Review 2.  Marine anticancer drugs and their relevant targets: a treasure from the ocean.

Authors:  Manisha Nigam; Hafiz Ansar Rasul Suleria; Mohammad Hosein Farzaei; Abhay Prakash Mishra
Journal:  Daru       Date:  2019-06-05       Impact factor: 3.117

3.  WNT/β-catenin Pathway Activation Correlates with Immune Exclusion across Human Cancers.

Authors:  Jason J Luke; Riyue Bao; Randy F Sweis; Stefani Spranger; Thomas F Gajewski
Journal:  Clin Cancer Res       Date:  2019-01-11       Impact factor: 12.531

Review 4.  GSK-3: a multifaceted player in acute leukemias.

Authors:  Alberto M Martelli; Camilla Evangelisti; Francesca Paganelli; Francesca Chiarini; James A McCubrey
Journal:  Leukemia       Date:  2021-04-02       Impact factor: 11.528

Review 5.  PD-1/PD-L1 pathway: current researches in cancer.

Authors:  Yanyan Han; Dandan Liu; Lianhong Li
Journal:  Am J Cancer Res       Date:  2020-03-01       Impact factor: 6.166

6.  BCL9/BCL9L promotes tumorigenicity through immune-dependent and independent mechanisms in triple negative breast cancer.

Authors:  Xiaoshuang Wang; Mei Feng; Tengfei Xiao; Baosen Guo; Danyang Liu; Chenglong Liu; Jinpeng Pei; Qiaofeng Liu; Yi Xiao; Rina Rosin-Arbesfeld; Ying Shi; Yang Zhou; Mengxuan Yang; Yu-Xiong Feng; Yizhou Jiang; Zhimin Shao; Ker Yu; Di Zhu
Journal:  Oncogene       Date:  2021-03-25       Impact factor: 9.867

Review 7.  Developmental pathways of myeloid-derived suppressor cells in neoplasia.

Authors:  Scott I Abrams
Journal:  Cell Immunol       Date:  2020-12-16       Impact factor: 4.868

8.  Vesicle transporter GOLT1B mediates the cell membrane localization of DVL2 and PD-L2 and promotes colorectal cancer metastasis.

Authors:  Tengfei Liu; Binbin Liu; Yiting Liu; Xingzhi Feng; Xuefei Jiang; Jiahui Long; Qianling Gao; Zihuan Yang
Journal:  Cancer Cell Int       Date:  2021-05-31       Impact factor: 5.722

9.  Reprogramming the immunosuppressive microenvironment of IDH1 wild-type glioblastoma by blocking Wnt signaling between microglia and cancer cells.

Authors:  Dandan Fan; Qi Yue; Jian Chen; Cong Wang; Ruilin Yu; Ziyi Jin; Shujie Yin; Qinyue Wang; Luo Chen; Xueling Liao; Chengyuan Peng; Jianpin Zhang; Zhonglian Cao; Ying Mao; Ruimin Huang; Liang Chen; Cong Li
Journal:  Oncoimmunology       Date:  2021-06-06       Impact factor: 8.110

10.  An Immunohistochemical Study of β-catenin Expression and Immune Cell Population in Metastatic Carcinoma to the Liver.

Authors:  Kwan-Yung Au; Regina Cheuk-Lam Lo
Journal:  Pathol Oncol Res       Date:  2021-06-04       Impact factor: 3.201
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.